Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

PARP-1/2 Inhibitor ABT-767

Known as: ABT-767 
An orally available inhibitor of the nuclear enzymes poly(ADP-ribose) polymerase (PARP) 1 and 2, with potential antineoplastic activity. Upon… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
OBJECTIVE Poly(ADP-ribose) polymerase (PARP) inhibitors have shown substantial activity in homologous recombination- (HR… Expand
2019
2019
Citation for published version (APA): van der Biessen, D. A. J., Gietema, J. A., de Jonge, M. J. A., Desar, I. M. E., den… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
2017
2017
SummaryPurpose This phase 1 study examined safety, pharmacokinetics (PK), and efficacy of the poly(ADP-ribose) polymerase (PARP… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
2017
2017
PurposeThe objective of the manuscript is to describe the development of a population pharmacokinetic model for ABT-767, a potent… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
2015
2015
BACKGROUND: Malignancies with homologous repair deficiency (HRD) are more dependent on PARP for DNA repair than normal cells… Expand
2014
2014
ABSTRACT Background: ABT-767 is a potent oral inhibitor of PARP-1 and -2. Malignancies with defects in homologous repair are more… Expand